Drug intelligence / Profile preview

PMV-3112

Development stage: Unknown
Lead developer: PMV Pharmaceuticals
Modality: Small Molecules

Overview

**PMV-3112** is a small molecule p53 inducer developed by PMV Pharmaceuticals for the treatment of cancers harboring mutant p53, particularly the Y220C mutation. It selectively reactivates mutant p53 protein, restoring its tumor-suppressive function and inducing anti-tumor activity. Preclinical and clinical data presented at the 2023 AACR Annual Meeting demonstrated its potential to stabilize and reactivate mutant p53, leading to tumor cell death in relevant models.

Targets

TP53 Y220C (Tumor suppressor protein p53 Y220C mutant)

Beyond the preview

Go deeper on PMV-3112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMV-3112.

Explore the full profile